Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENECA: Allo-MSCs in Anthracycline-Induced Cardiomyopathy
NCT02509156Phase 1Completed
- Sponsor
- UTHealth Houston
- Start
- Aug 2016
- Primary completion
- Nov 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MSV alogénicas in anthracycline-induced cardiomyopathy (AIC) (3 arms), sponsored by UTHealth Houston. Primary endpoints: Major Adverse Cardiac Events at 12 months and Other Significant Clinical Events at 12 months. Started Aug 2016; status: completed.
02
Drugs
MSV alogénicas
03
Conditions
anthracycline-induced cardiomyopathy (AIC)
Beyond the preview
Go deeper on NCT02509156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02509156.